LEADER 04574nam 2200601Ia 450 001 9910807741603321 005 20230725054529.0 010 $a1-61728-045-3 035 $a(CKB)2550000000080166 035 $a(EBL)3018101 035 $a(SSID)ssj0000742377 035 $a(PQKBManifestationID)12315868 035 $a(PQKBTitleCode)TC0000742377 035 $a(PQKBWorkID)10778945 035 $a(PQKB)11766619 035 $a(MiAaPQ)EBC3018101 035 $a(Au-PeEL)EBL3018101 035 $a(CaPaEBR)ebr10659023 035 $a(OCoLC)923655083 035 $a(EXLCZ)992550000000080166 100 $a20130317d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvances in medicine and biology$b[electronic resource] $hVolume 6 /$fLeon V. Berhardt, editor 210 $aNew York $cNova Biomedical Books$dc2010 215 $a1 online resource (296 p.) 225 1 $aAdvances in Medicine and Biology ;$vv.6 300 $aDescription based upon print version of record. 311 $a1-61668-970-6 320 $aIncludes bibliographical references and index. 327 $a""ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6""; ""CONTENTS""; ""PREFACE""; ""ZINC-BASED BIOMATERIALS""; ""BIOLOGICAL ASPECTS OF ZINC""; ""ZINC BIOMATERIALS""; ""ZINC OXYCHLORIDE CEMENTS""; ""ZINC OXIDE EUGENOL CEMENTS""; ""ZINC PHOSPHATE CEMENTS""; ""ZINC POLYCARBOXYLATE CEMENTS""; ""GLASS POLY(ALKENOATE) CEMENTS""; ""GLASSES USED IN GPCS""; ""ACID COMPONENTS USED IN GPCS""; ""THE ROLE OF ADDITIVES TO GPCS""; ""MECHANICAL PROPERTIES OF GPCS""; ""BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS""; ""ALUMINIUM FREE GPCS""; ""STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES"" 327 $a""STRENGTH OF ALUMINIUM-FREE GPCS""""OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS""; ""IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""OTHER ASPECTS OF ALUMINIUM-FREE GPCS""; ""APPLICATIONS FOR ALUMINIUM-FREE GPCS""; ""FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS""; ""REFERENCES""; ""THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA""; ""ABSTRACT""; ""INTRODUCTION""; ""NEUROANATOMY OF SPEECH AND LANGUAGE""; ""NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE""; ""The Primary Neurotransmitters"" 327 $a""Glutamate, I?³-Aminobutyric Acid and Glycine""""Neuromodulators and Hormones""; ""Catecholamines""; ""Acetylcholine""; ""Serotonin""; ""DEFINITION OF FLUENCY""; ""NEUROPHARMACOLOGY OF VERBAL FLUENCY, SPEECH ANDLANGUAGE""; ""Agents which Increase Cerebral Perfusion""; ""Dopaminergic Agents""; ""Amphetamines""; ""Serotonin""; ""Cholinergic Drugs""; ""Piracetam""; ""Zolpidem""; ""Amantadine""; ""Antiepileptic Agents""; ""Drugs which have Speech and Language Side Effects""; ""CLINICAL CASE""; ""CONCLUSION""; ""REFERENCES""; ""PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE""; ""ABSTRACT"" 327 $a""1. CLINICAL FEATURES OF PSORIASIS""""2. TREATMENT OPTIONS FOR PSORIASIS""; ""3. PATHOGENESIS OF PSORIASIS""; ""4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORYDISORDERS""; ""5. CLINICAL LINK BETWEEN PSORIASIS ANDATHEROSCLEROSIS""; ""6. OPHTHALMIC AND RENAL MANIFESTATIONS OFPSORIASIS""; ""7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OFPSORIASIS AND OTHER INFLAMMATORY DISORDERS""; ""8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITSSYSTEMIC MANIFESTATION?""; ""9. DELINEATING PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE: ""5 YEAR VIEW""""; ""REFERENCES"" 327 $a""REPACKAGING OF ANTI-GLAUCOMAMEDICINES:NEW THERAPEUTIC VISTAS""""ABSTRACT""; ""INTRODUCTION""; ""CHOLINERGIC AGENTS""; ""Pilocarpine""; ""NON-SELECTIVE ADRENERGIC AGONISTS""; ""CARBONIC ANHYDRASE INHIBITORS""; ""Acetazolamide""; ""Dorzolamide and Brinzolamide""; ""I?±2-ADRENERGIC AGONIST""; ""BETA-BLOCKING AGENTS""; ""Timolol""; ""Betaxolol""; ""Levobunolol""; ""Carteolol""; ""PROSTAGLANDIN ANALOGS""; ""Unoprostone Isopropylate""; ""Latanoprost""; ""COMBIMATION""; ""CONCLUSION""; ""REFERENCES""; ""THE UTILIZATION OF TECHNOLOGY IN THETREATMENT OF OBSESSIVE COMPULSIVEDISORDER""; ""ABSTRACT"" 327 $a""INTRODUCTION"" 410 0$aAdvances in Medicine and Biology 606 $aMedicine 606 $aBiology 615 0$aMedicine. 615 0$aBiology. 676 $a616 701 $aBerhardt$b Leon V$01638158 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910807741603321 996 $aAdvances in medicine and biology$93980405 997 $aUNINA